Lung cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), the so-called Big-3 (B3), are expected to cause most deaths by 2050. Early detection and prevention are crucial to lower the disease burden. Innovative low-dose computed tomography (CT) allows simultaneous, integrated assessment of early imaging biomarkers of lung cancer, COPD and CVD. Major advantages of integrated B3 screening are expected due to shared risk factors, B3 interdependence and health economic yield comparison to single disease screening. However, a major impediment before establishing a B3 screening program is the lack of validated and standardized B3 imaging biomarkers. The aim of this project is to advance the technology readiness level (TRL) of integrated B3 screening with at least 2 levels. To reach this objective, B3CARE will develop a large, high-quality imaging data biobank to provide biomarker reference values and validate B3 biomarkers using novel image analysis software and novel machine learning approaches. This will accelerate software development for CT-imaging data post-processing. Also, the expected substantial health economics potential of combined B3 imaging biomarkers for personalized health strategies is evaluated. B3CARE will thus provide an invaluable resource for the accelerated development and implementation of B3 imaging biomarkers and computer aided decision support.